BNTX Jan 2025 105.000 put
| Previous close | 18.40 |
| Open | 18.76 |
| Bid | 18.00 |
| Ask | 21.20 |
| Strike | 105.00 |
| Expiry date | 2025-01-17 |
| Day's range | 18.40 - 18.76 |
| Contract range | N/A |
| Volume | |
| Open interest | 1.6k |
Insider Monkey25 Richest Billionaires in Healthcare Industry
In this article, we discuss the 25 richest billionaires in healthcare industry. To skip the detailed analysis of the healthcare industry, go directly to the 5 Richest Billionaires in Healthcare Industry. Global Healthcare Industry Outlook and Trends The global healthcare industry is going through a massive transition amid technological advancements, changing patient needs, and demographic […]
Globe NewswireBioNTech to Report First Quarter 2024 Financial Results and Corporate Update on May 6, 2024
MAINZ, Germany, April 22, 2024 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the first quarter 2024 on Monday, May 6, 2024. Additionally, the Company will host a conference call and webcast that day at 8:00 a.m. EDT (2:00 p.m. CEST) for investors, financial analysts and the general public to discuss its financial results and provide a corporate update. To access the live conference call via telephone, please register via this
- Globe Newswire
Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persistence of Immune Response and Delayed Tumor Recurrence in Some Patients with Resected Pancreatic Cancer
Three-year follow-up data of an investigator-initiated Phase 1 trial of the individualized mRNA cancer vaccine candidate autogene cevumeran (BNT122, RO7198457) continue to show polyspecific T cell responses up to three years and delayed tumor recurrence in patients with resected pancreatic ductal adenocarcinoma (“PDAC”)A randomized Phase 2 clinical trial with autogene cevumeran in patients with resected PDAC is currently enrolling patients at clinical trial sites in the United States, with addit
